Waters[™]

Applikationsbericht

A Sensitive and Rapid Estimation of Leuprolide in Human Plasma Using UPLC and Xevo TQ-S

Veeranjaneyulu P., Rao B. Tirupateswara, Sudarshan Mantha, Gopal Vaidyanathan

Waters Corporation



Abstract

In this study, we demonstrate detection of leuprolide in human plasma at very low concentrations using a Waters ACQUITY UPLC and Xevo TQ-S tandem quadrupole system, which is able to deliver the required sensitivity for this challenging assay.

Benefits

A unique optimization of this Waters system for bioanalysis, from sample preparation to UPLC chromatography to tandem quadrupole MS, enables the determination and quantification of leuprolide at the 5 pg/mL level.

Introduction

Leuprolide is a synthetic nonapeptide that acts as an agonist at pituitary GnRH receptors. Leuprolide downregulates the secretion of gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by interrupting the normal pulsatile stimulation and the desensitization of the GnRH receptors.

An LH-RH (GnRH) analog, leuprolide (Figure 1) may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids) to treat precocious puberty, and also to control ovarian stimulation in vitro fertilization (IVF). It is also considered a possible treatment for paraphilias.




Figure 1. Leuprolide structure.

Leuprolide received its first approval for treatment of advanced prostate cancer in 1985 and received several other approvals for treating prostate cancer at several dosage levels. However, monitoring leuprolide and its analytes in its low-dosage concentration had not been possible because analytical techniques were not able

to offer the necessary sensitivity.

In this study, we demonstrate detection of leuprolide in human plasma at very low concentrations using a Waters ACQUITY UPLC and Xevo TQ-S tandem quadrupole system, which is able to deliver the required sensitivity for this challenging assay.

Experimental

LC conditions

LC system:	ACQUITY UPLC System equipped with a Binary Solvent Manager, Column Manager, and Sample Manager	
LC column:	ACQUITY UPLC BEH 300 C ₁₈ , 2.1 x 100 mm, 1.7 μ m	
Gradient:	Reversed-phase chromatography with an acidic aqueous buffer solution and acetonitrile as the organic modifier	
Elution:	30-95% organic gradient over 3.5 min	
LC gradient run:	5.0 min starting with 90% acid solution and 10% acetonitrile	
Column temp.:	50 °C	
MS conditions		
MS system:	Xevo TQ-S	
MS mode:	Positive ion electrospray MS/MS	

MS transition:

$605.69 \Rightarrow 249.11$

When compared to an HPLC, UPLC Technology enables a user to achieve faster separations with lower consumption of the mobile phase. UPLC also offers short run times with low dispersion, resulting in better separation of signals from unwanted signals arising from plasma, phospholipids, and other endogenous materials. In addition, the ACQUITY UPLC BEH 300 Column used in this study offers significantly better separation of peptides when compared to traditional reversed phase columns.

For mass spectrometry, the Xevo TQ-S offers the advantage of high sensitivity and its ZSpray Technology provides added stability to the analysis. The combined effect of the outstanding UPLC column chemistry and chromatographic system along with the Xevo TQ-S provides a powerful tool for the estimation of a variety of molecules, from small molecules to large peptides, in very low concentrations.

Results and Discussion

The leuprolide analyte eluted with a retention time of 1.75 min. As can be observed from Figure 2, the leuprolide signal shows excellent symmetrical peak shape and resolution from endogenous interferences. Such excellent peak shape and chromatographic resolution can be attributed to an optimized combination of the ACQUITY UPLC System and BEH 300 C₁₈ Column.

The LLOQ for leuprolide was determined to be 5 pg/mL with the signal-to-noise ratio being at least 20:1 (Figure 2). In addition, the results showed excellent reproducibility at LLOQ levels (Table 1). Such excellent reproducibility and sensitivity provides the ability to quantify leuprolide at the LLOQ level.




Figure 2. UPLC-MS/MS chromatogram of leuprolide showing signal-to-noise ratio of greater than 20 at the LLOQ level.

Sample Name	Standard Conc.	Calculated Conc.	% Deviation	% Recovery
Reference	650	610.1	-6.1	93.9
CC 1	5	5	-0.2	99.8
CC 2	10	10.2	2.3	102.3
CC 3	25	23.5	-5.9	94.1
CC 4	50	50.9	1.9	101.9
CC 5	100	107.6	7.6	107.6
CC 6	150	136.4	-9.1	90.9
CC 7	325	319.8	-1.6	98.4
CC 8	650	683.3	5.1	105.1
LLOQQC-1	6	6.4	6.9	106.9
LQC-1	15	15.7	4.5	104.5
MQC-1	120	115.4	-3.9	96.1
HQC-1	475	536.2	12.9	112.9
LLOQQC-2	6	6.9	14.6	114.6
LQC-2	15	14.9	-0.5	99.5
MQC-2	120	104.9	-12.6	87.4
HQC-2	475	462.8	-2.6	97.4
LLOQQC-3	6	5.6	-6.6	93.4
LQC-3	15	15.3	2	102
MQC-3	120	114.8	-4.4	95.6
HQC-3	475	511.9	7.8	107.8
LLOQQC-4	6	5.3	-11.4	88.6
LQC-4	15	16.3	8.9	108.9
MQC-4	120	103.6	-13.6	86.4
HQC-4	475	471.3	-0.8	99.2
LLOQQC-5	6	6.7	10.9	110.9
LQC-5	15	15.9	5.7	105.7
MQC-5	120	109.8	-8.5	91.5
HQC-5	475	536.8	13	113
LLOQQC-6	6	6	0.4	100.4
LQC-6	15	13.9	-7.1	92.9
MQC-6	120	104.3	-13	87
HQC-6	475	470.5	-1	99

 Table 1. Comparison of calculated with standard concentration, percent deviation, and percent

 recovery for leuprolide samples at various concentration levels using UPLC and Xevo TQ-S.

The LLOQ obtained for this analysis was due, in part, to the high-sensitivity detection provided by the Xevo TQ-S System. The co-joined, off-axis StepWave ion guide in the Xevo TQ-S provides superior levels of

sensitivity while maintaining the robustness and cleanliness of the source and ion optics. This enables the Xevo TQ-S to increase the ion flux entering the mass spectrometer, resulting in the highest levels of sensitivity. The assay reported in this study was demonstrated to be linear over the range of 5 to 650 pg/mL in both organic solvents and human plasma samples.

As observed from Table 1, the %RSD varied from 4.887 to 6.874 within a range of concentration. Although the inter-day precision varied between 2.130 and 9.475 for the lowest level of concentration, the medium, high-concentration ranges and the LLOQQC showed a variation within the range of 5.128 to 9.927. In addition, the percent recovery of samples that was conducted by comparing the area under the curve of the extracted sample with that of the neat sample, was found to be about 60% at all concentration levels.

The LC-MS/MS chromatogram of the blank plasma sample and that of the leuprolide at LLOQ level showed little interference from the endogenous materials (Figure 3 and Figure 4). In addition, phospholipid elution was checked by injecting an extracted standard with an MS scan at $184 \Rightarrow 184 \text{ m/z}$, a unique MRM transition for typical phospholipids. As can be observed from Figure 5, no significant phospholipid elution was observed at the retention time of either the leuprolide analyte (1.75 min) or the internal standard, octreotide (1.63 min).

Matrix interference, which is considered to be one of the major regulatory challenges in the pharmaceutical world, is automatically calculated by MassLynx Software. A comparison of the post-spiked samples with those of the neat samples in the same concentration level reveals that the matrix interference for the Leuprolide samples was not more than 2.051%. Such a value is well within the acceptable range indicated by the regulatory agencies.




Figure 3. Representative chromatogram of blank in leuprolide channel.




Figure 4. Representative chromatogram of leuprolide at LLOQ.




Figure 5. Comparsion of phospholipid elution with respect to leuprolide (analyte) and its IS, octreotide.

Conclusion

The low circulating concentration levels of leuprolide, a synthetic nonapeptide that acts as an agonist at pituitary GnRH receptors, requires a highly sensitive assay for accurate determination of the pharmacokinetics in humans, especially in prostate cancer patients.

This study demonstrates that the combination of Oasis SPE Technology, the ACQUITY UPLC System with a BEH 300 C₁₈ column, and the Xevo TQ-S Mass Spectrometer combine to enable the development of an assay for Leuprolide with an LLOQ of 5 pg/mL in human plasma.

The UPLC chromatograms demonstrate not only better chromatography, but also better resolution compared to the data obtained from any conventional HPLC systems. The assay reported in this study showed excellent reproducibility, specificity, and robustness. Despite the complicated nature of this analytical challenge, the overall cycle time for the UPLC-MS/MS experiments reported in this study was about 3 minutes.

References

- MacNeill R, Evans E. Evaluation of acetone as organic modifier in SPE for bioanalytical quantitative LC-MS/MS. *Bioanalysis*. 2011 Feb; 3(3):291-300.
- Adjei A, Doyle R, Pratt M, Finley R, Johnson E. Bioavailability of leuprolide following intratracheal administration to beagle dogs. *International Journal of Pharmaceutics*. Vol 61, Issues 1-2, 11 June 1990: 135-144.
- Zhan Y, Chen X, Zhao X, Zhong D. Rapid and sensitive liquid chromatography- tandem mass spectrometry method for the determination of leuprolide in human serum. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Oct 1;877(27):3194-200. Epub 2009 Aug 21.
- Bhatia S, Neely EK, Wilson DM. Serum Luteinizing Hormone Rises Within Minutes After Depot Leuprolide Injection: Implications for Monitoring Therapy. *Pediatrics* Vol. 109 No. 2 February 2002. http://www.pediatrics.org/cgi/ content/full/109/2/e30.

Featured Products

ACQUITY UPLC System <https://www.waters.com/514207> Xevo TQ-S <https://www.waters.com/10160596>

720004094, August 2011

©2019 Waters Corporation. All Rights Reserved.